{"protocolSection":{"identificationModule":{"nctId":"NCT00718315","orgStudyIdInfo":{"id":"ML21450"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.","officialTitle":"A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer."},"statusModule":{"statusVerifiedDate":"2015-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-04"},"primaryCompletionDateStruct":{"date":"2012-06","type":"ACTUAL"},"completionDateStruct":{"date":"2012-06","type":"ACTUAL"},"studyFirstSubmitDate":"2008-07-16","studyFirstSubmitQcDate":"2008-07-16","studyFirstPostDateStruct":{"date":"2008-07-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-01-09","resultsFirstSubmitQcDate":"2015-01-09","resultsFirstPostDateStruct":{"date":"2015-01-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-09","lastUpdatePostDateStruct":{"date":"2015-01-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell lung cancer. Eligible patients who have recently started Tarceva treatment will be randomized to one of 3 groups, to receive daily treatment with Verutex, Eritex or Fisiogel cream for 30 days, and the incidence and severity of skin rash will be assessed. The anticipated time on study treatment is \\<3 months, and the target sample size is 100-500 individuals."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":201,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: fusidic acid [Verutex]"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: erythromycin [Eritex]"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: Fisiogel"]}],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150mg po daily","armGroupLabels":["1","2","3"]},{"type":"DRUG","name":"fusidic acid [Verutex]","description":"topical, daily for 30 days.","armGroupLabels":["1"]},{"type":"DRUG","name":"erythromycin [Eritex]","description":"topical, daily for 30 days.","armGroupLabels":["2"]},{"type":"DRUG","name":"Fisiogel","description":"topical, daily for 30 days","armGroupLabels":["3"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Who Develop Skin Rash","description":"Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line \"Rash/desquamation\" - short name \"rash\").","timeFrame":"30 Days"},{"measure":"Percentage of Participants With Skin Rash Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death","timeFrame":"30 Days"}],"secondaryOutcomes":[{"measure":"Time to Appearance of Skin Rash","description":"Time to occurence of skin rash was calculated as the number of days from Day 0 until the first appearance of skin rash as defined by NCI-CTCAE","timeFrame":"Days 0, 15, and 30"},{"measure":"Percentage of Participants With Erythema","description":"Erythema is defined as redness of the skin or mucous membranes, caused by hyperemia of superficial capillaries","timeFrame":"Days 0, 15, and 30"},{"measure":"Percentage of Participants With Pruritus","description":"Pruritus is defined as intense localized itching","timeFrame":"Days 0, 15, and 30"},{"measure":"Percentage of Participants With Pain","description":"Pain is defined as an unpleasant feeling often caused by intense or damaging stimuli","timeFrame":"Days 0, 15, and 30"},{"measure":"Percentage of Participants With Erythema Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","timeFrame":"30 Days"},{"measure":"Percentage of Participants With Pruritus Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","timeFrame":"30 Days"},{"measure":"Percentage of Participants With Pain Stratified by Severity Grade","description":"The severity of pain was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","timeFrame":"30 Days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV);\n* eligible to start treatment with Tarceva, or receiving Tarceva for \\<=5 days.\n\nExclusion Criteria:\n\n* presence of skin rash or other signs of skin toxicity;\n* treatment with any systemic or intranasal antibiotic within 7 days before randomization;\n* treatment with other topical formulation within 14 days before randomization;\n* other anticancer therapy in addition to Tarceva.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Fortaleza","state":"Ceará","zip":"60125-151","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"city":"Fortaleza","state":"Ceará","zip":"60190-800","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"city":"Salvador","state":"Estado de Bahia","zip":"40110-150","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"city":"Salvador","state":"Estado de Bahia","zip":"40170-110","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"city":"Salvador","state":"Estado de Bahia","zip":"41950-610","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"city":"Taguatinga","state":"Federal District","zip":"72115-700","country":"Brazil","geoPoint":{"lat":-15.83326,"lon":-48.05506}},{"city":"Goiânia","state":"Goiás","zip":"74140-050","country":"Brazil","geoPoint":{"lat":-16.67861,"lon":-49.25389}},{"city":"Belo Horizonte","state":"Minas Gerais","zip":"30150-281","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"city":"Belo Horizonte","state":"Minas Gerais","zip":"30150-321","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"city":"Divinópolis","state":"Minas Gerais","zip":"35500-222","country":"Brazil","geoPoint":{"lat":-20.14355,"lon":-44.89065}},{"city":"Curitiba","state":"Paraná","zip":"80010030","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"city":"Curitiba","state":"Paraná","zip":"80810-050","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"city":"Recife","state":"Pernambuco","zip":"50070-170","country":"Brazil","geoPoint":{"lat":-8.05389,"lon":-34.88111}},{"city":"Rio de Janeiro","state":"Rio de Janeiro","zip":"22260-020","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"city":"Rio de Janeiro","state":"Rio de Janeiro","zip":"22290-160","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"city":"Natal","state":"Rio Grande do Norte","zip":"59040150","country":"Brazil","geoPoint":{"lat":-5.795,"lon":-35.20944}},{"city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90430-090","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"city":"Itajaí","state":"Santa Catarina","zip":"88301-220","country":"Brazil","geoPoint":{"lat":-26.90778,"lon":-48.66194}},{"city":"Ribeirão Preto","state":"São Paulo","zip":"14025-270","country":"Brazil","geoPoint":{"lat":-21.1775,"lon":-47.81028}},{"city":"São Paulo","state":"São Paulo","zip":"01221-020","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"São Paulo","state":"São Paulo","zip":"01308-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"São Paulo","state":"São Paulo","zip":"01323-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"São Paulo","state":"São Paulo","zip":"01406100","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"São Paulo","state":"São Paulo","zip":"04039-901","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"São Paulo","state":"São Paulo","zip":"05652-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Fisiogel","description":"Participants received erlotinib 150 milligrams (mg) daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"FG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"FG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"67"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"21"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Erlotinib dose decreased","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Use of Minocyclin","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Use of ATB and Corticoids","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intention to treat (ITT) population covered all participants who had at least one application of study drug and who had at least one post-treatment assessment, irrespective of compliance extent with protocol criteria.","groups":[{"id":"BG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"BG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"BG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"67"},{"groupId":"BG003","value":"201"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.3","spread":"11.1"},{"groupId":"BG001","value":"63.6","spread":"11.0"},{"groupId":"BG002","value":"64.6","spread":"14.0"},{"groupId":"BG003","value":"64.7","spread":"12.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"94"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"107"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Develop Skin Rash","description":"Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line \"Rash/desquamation\" - short name \"rash\").","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"30 Days","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","lowerLimit":"47.1","upperLimit":"72.0"},{"groupId":"OG001","value":"69.2","lowerLimit":"56.6","upperLimit":"80.1"},{"groupId":"OG002","value":"73.1","lowerLimit":"60.9","upperLimit":"83.2"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.481","pValueComment":"Test for Binomial Ratio, where H0: P \\>=61%; Ha: P \\< 61% (One-tailed Test)","statisticalMethod":"t-test, 1 sided"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.933","pValueComment":"Test for Binomial Ratio, where H0: P \\>=61%; Ha: P \\< 61% (One-tailed Test)","statisticalMethod":"t-test, 1 sided"},{"groupIds":["OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.986","pValueComment":"Test for Binomial Ratio, where H0: P \\>=61%; Ha: P \\< 61% (One-tailed Test)","statisticalMethod":"t-test, 1 sided"}]},{"type":"PRIMARY","title":"Percentage of Participants With Skin Rash Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"30 Days","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"}]}],"classes":[{"title":"Grade 0","categories":[{"measurements":[{"groupId":"OG000","value":"29.8"},{"groupId":"OG001","value":"25.0"},{"groupId":"OG002","value":"18.3"}]}]},{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"21.1"},{"groupId":"OG001","value":"18.3"},{"groupId":"OG002","value":"43.3"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"49.1"},{"groupId":"OG001","value":"56.7"},{"groupId":"OG002","value":"35.0"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3.3"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Time to Appearance of Skin Rash","description":"Time to occurence of skin rash was calculated as the number of days from Day 0 until the first appearance of skin rash as defined by NCI-CTCAE","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Days","timeFrame":"Days 0, 15, and 30","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"15.0","upperLimit":"28.0"},{"groupId":"OG001","value":"15.0","lowerLimit":"15.0","upperLimit":"16.0"},{"groupId":"OG002","value":"15.0","lowerLimit":"14.0","upperLimit":"15.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.095","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Percentage of Participants With Erythema","description":"Erythema is defined as redness of the skin or mucous membranes, caused by hyperemia of superficial capillaries","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 15, and 30","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","lowerLimit":"44.8","upperLimit":"67.9"},{"groupId":"OG001","value":"56.7","lowerLimit":"44.8","upperLimit":"67.9"},{"groupId":"OG002","value":"43.3","lowerLimit":"32.1","upperLimit":"55.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.199","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"Percentage of Participants With Pruritus","description":"Pruritus is defined as intense localized itching","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 15, and 30","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","lowerLimit":"25.2","upperLimit":"48.6"},{"groupId":"OG001","value":"47.6","lowerLimit":"35.8","upperLimit":"59.7"},{"groupId":"OG002","value":"29.5","lowerLimit":"19.6","upperLimit":"41.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.108","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain","description":"Pain is defined as an unpleasant feeling often caused by intense or damaging stimuli","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 15, and 30","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"9.4","upperLimit":"27.1"},{"groupId":"OG001","value":"25.4","lowerLimit":"16.5","upperLimit":"36.9"},{"groupId":"OG002","value":"13.4","lowerLimit":"7.2","upperLimit":"23.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.179","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"Percentage of Participants With Erythema Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"30 Days","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Grade 0","categories":[{"measurements":[{"groupId":"OG000","value":"37.7"},{"groupId":"OG001","value":"39.7"},{"groupId":"OG002","value":"52.5"}]}]},{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"36.5"},{"groupId":"OG002","value":"39.3"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"6.6"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"1.6"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.066","statisticalMethod":"Kruskal-Wallis"}]},{"type":"SECONDARY","title":"Percentage of Participants With Pruritus Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"30 Days","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Grade 0","categories":[{"measurements":[{"groupId":"OG000","value":"63.9"},{"groupId":"OG001","value":"52.4"},{"groupId":"OG002","value":"70.5"}]}]},{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"19.7"},{"groupId":"OG001","value":"31.7"},{"groupId":"OG002","value":"24.6"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"14.8"},{"groupId":"OG001","value":"14.3"},{"groupId":"OG002","value":"3.3"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"1.6"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.087","statisticalMethod":"Kruskal-Wallis"}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain Stratified by Severity Grade","description":"The severity of pain was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"30 Days","groups":[{"id":"OG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days."},{"id":"OG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Grade 0","categories":[{"measurements":[{"groupId":"OG000","value":"82.0"},{"groupId":"OG001","value":"73.0"},{"groupId":"OG002","value":"85.2"}]}]},{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"11.5"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"6.6"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"4.8"},{"groupId":"OG002","value":"6.6"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1.6"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.308","statisticalMethod":"Kruskal-Wallis"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse Events were recorded from Day 0 to Day 45 (15 days after the End of study)","eventGroups":[{"id":"EG000","title":"Fisiogel","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Fisiogel was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days.","seriousNumAffected":12,"seriousNumAtRisk":67,"otherNumAffected":45,"otherNumAtRisk":67},{"id":"EG001","title":"Stiemicyn","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Stiemicyn was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days.","seriousNumAffected":13,"seriousNumAtRisk":66,"otherNumAffected":45,"otherNumAtRisk":66},{"id":"EG002","title":"Verutex","description":"Participants received erlotinib 150 mg daily and A thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days","seriousNumAffected":19,"seriousNumAtRisk":67,"otherNumAffected":48,"otherNumAtRisk":67}],"seriousEvents":[{"term":"Fatigue (asthenia, lethargy, malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Pericardial effusion (non-malignant)","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Fever (in the absence of neutropenia, where neurtropenia is defined as ANC <1.0x109/L)","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Death not associated with CTCAE term","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":3,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Death not associated with CTCAE term - \"cardiac arrest\"","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Ascites (non-malignant)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Obstruction, GI - small bowel NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"No specification","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Hemorrhage, pulmonary/upper respiratory, bronchopulmonary NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Hemorrhage, GI, lower GI NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Hemorrhage, GI, stomach","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Hemorrhage, pulmonary/upper respiratory, respiratory tract NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Lung (pneumonia)","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Pulmonary/upper respiratory","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"CNS cerebrovascular ischemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Confusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification, pulmonary/upper respiratory, pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification, cardiovascular, pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Adult respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Dyspnea (shortness of breath)","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":4,"numAtRisk":67}]},{"term":"Pleural effusion (non-malignant)","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Disease progression NOS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Thrombosis/thrombus/embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Vessel injury - vein - SVC","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]}],"otherEvents":[{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":67},{"groupId":"EG001","numAffected":18,"numAtRisk":66},{"groupId":"EG002","numAffected":14,"numAtRisk":67}]},{"term":"Anorexia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":67},{"groupId":"EG001","numAffected":7,"numAtRisk":66},{"groupId":"EG002","numAffected":6,"numAtRisk":67}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":67},{"groupId":"EG001","numAffected":4,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"Mucositis/stomatitis (clinical exam) - oral cavity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":5,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":4,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Mucositis/stomatitis (functional/symptomatic) - oral cavity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"Dry mouth/salivary gland (xerostomia)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Dyspnea (shortness of breath)","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":67},{"groupId":"EG001","numAffected":4,"numAtRisk":66},{"groupId":"EG002","numAffected":4,"numAtRisk":67}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":67},{"groupId":"EG001","numAffected":7,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"No specification","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":4,"numAtRisk":67}]},{"term":"Adult respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Pleural effusion (non-malignant)","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Fatigue (asthenia, lethargy, malaise)","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":67},{"groupId":"EG001","numAffected":8,"numAtRisk":66},{"groupId":"EG002","numAffected":4,"numAtRisk":67}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"No specification","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":4,"numAtRisk":67}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"Nail change","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":3,"numAtRisk":66},{"groupId":"EG002","numAffected":0,"numAtRisk":67}]},{"term":"Lung (pneumonia)","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Pulmonary/upper respiratory","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":4,"numAtRisk":66},{"groupId":"EG002","numAffected":6,"numAtRisk":67}]},{"term":"Renal/genitourinary","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":3,"numAtRisk":67}]},{"term":"No specification","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"No specification","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":4,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"No specification","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"No specification","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Death not associated with CTCAE term","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":3,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"Dry eye syndrome","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":67},{"groupId":"EG001","numAffected":0,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]},{"term":"Hemoglobin","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":67},{"groupId":"EG001","numAffected":2,"numAtRisk":66},{"groupId":"EG002","numAffected":2,"numAtRisk":67}]},{"term":"No specification","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":67},{"groupId":"EG001","numAffected":1,"numAtRisk":66},{"groupId":"EG002","numAffected":1,"numAtRisk":67}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann- LaRoche","email":"genentech@druginfo.com","phone":"1-800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D005672","term":"Fusidic Acid"},{"id":"D004917","term":"Erythromycin"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D002775","term":"Cholestadienols"},{"id":"D002774","term":"Cholestadienes"},{"id":"D002782","term":"Cholestenes"},{"id":"D002776","term":"Cholestanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D013261","term":"Sterols"},{"id":"D008563","term":"Membrane Lipids"},{"id":"D008055","term":"Lipids"},{"id":"D018942","term":"Macrolides"},{"id":"D061065","term":"Polyketides"},{"id":"D007783","term":"Lactones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}